Why the study?
Endoplasmic reticulum and mitochondria are stressed in IPF, but no data were available regarding ER-mitochondrial cross talk and tethering under conditions of IPF.
Does capsaicin treatment restore PACS2 levels and reduce alveolar epithelial apoptosis in models of idiopathic pulmonary fibrosis?
Does capsaicin treatment restore PACS2 levels and reduce alveolar epithelial apoptosis in models of idiopathic pulmonary fibrosis?
Therapeutic targeting of the PACS2-TRPV1 axis with capsaicin represents a potential epithelial-protective approach in idiopathic pulmonary fibrosis by restoring ER-mitochondrial tethering and reducing apoptosis.
Does not support clinical translation in IPF; leaves open whether restoring ER-mito tethering modifies disease progression.
Endoplasmic reticulum (ER) and mitochondria (mito) play a vital role in alveolar type II cell (AEC2) homeostasis and are both stressed in patients with idiopathic pulmonary fibrosis (IPF). Up to now, no data are available with regard to ER–mito cross talk and tethering under conditions of IPF. We here demonstrate that ER–mitochondrial tethering is reduced upon experimental ER stress in vitro and in the IPF AECII ex vivo, and this is—at least in part—due to decreased phosphofurin acidic cluster sorting protein 2 (PACS-2, also called PACS2) protein levels. PACS2 levels are influenced by its interaction with the transient receptor potential cation channel subfamily V member 1 (TRPV1) and can be experimentally modified by the TRPV1-modulating drug capsaicin (CPS). Employing alveolar epithelial cells with overexpression of the terminal ER stress signaling factor Chop or the IPF-associated surfactant protein C mutation (SPC Δexon4 ) in vitro, we observed a restoration of PACS2 levels upon treatment with CPS. Similarly, treatment of precision cut lung slices from IPF patients with CPS ex vivo forwarded similar effects. Importantly, in all models such kind of intervention also greatly reduced the extent of alveolar epithelial apoptosis. We therefore conclude that therapeutic targeting of the PACS2–TRPV1 axis represents an interesting novel, epithelial-protective approach in IPF.
No takes yet. Share an insight, caveat, or question.
Knoell et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: